Aficamten Wins UK Authorization and NICE Access

Company Cytokinetics Event Type Regulatory Authorization and Reimbursement Recommendation (UK) Modality Small-molecule cardiac myosin inhibitor Asset Aficamten Target Cardiac myosin Disease Area Symptomatic obstructive hypertrophic cardiomyopathy Summary The UK regulator authorized aficamten for eligible adults with symptomatic obstructive hypertrophic cardiomyopathy, while NICE simultaneously recommended NHS…